Table 4.
Prostate cancer trial cost-utility analysis.
|
|
Intervention group (n=75) |
Control group (n=75) |
|
|
|
||||||
|
|
Mean (SD) | Mean (SD) | P valuea | t test (df) | 95% CI | ||||||
| Health utility |
|
|
|
|
|
||||||
|
|
QALYsb,c | –0.0008 (0.0006) | –0.0009 (0.0006) | <.0001 | 6.419 (1998) | 0.0001 to 0.0002 | |||||
|
|
Incremental QALYsb | 0.0002 (0.0008) | N/Ad | N/A | N/A | N/A | |||||
| Costs (€e) |
|
|
|
|
|
||||||
|
|
Intervention costs | 43 (0.2) | N/A | N/A | N/A | N/A | |||||
| All health care costsf (€) |
|
|
|
|
|
||||||
|
|
Outpatient | 2077 (1386) | 2488 (2403) | N/A | N/A | N/A | |||||
|
|
Inpatient | 1321 (5460) | 1049 (4240) | N/A | N/A | N/A | |||||
|
|
Total | 3419 (739) | 3537 (689) | .0002 | –4 (1988) | –183 to –57 | |||||
|
|
Incrementalb | –120 (1034) | N/A | N/A | N/A | N/A | |||||
| Acute health care costs (€) |
|
|
|||||||||
|
|
Outpatient | 121 (247) | 126 (258) | N/A | N/A | N/A | |||||
|
|
Inpatient | 1054 (5132) | 684 (2335) | N/A | N/A | N/A | |||||
|
|
Total | 1219 (593) | 802 (281) | <.0001 | 20 (1426) | 376 to 458 | |||||
|
|
Incrementalb | 417 (659) | N/A | N/A | N/A | N/A | |||||
| ICERab | –1,092,136 (35,155,229) | N/A | N/A | N/A | –3,274,774 to 1,090,502 | ||||||
| ICERbb | 745,987 (16,006,924) | N/A | N/A | N/A | –247,317 to 1,739,292 | ||||||
| ICERcb | 13,118 (1,314,743) | N/A | N/A | N/A | –68,468 to 94,704 | ||||||
aIndependent unpaired samples Student t test (2-tailed).
bBased on bootstrap.
cQALY: quality-adjusted life year.
dN/A: not applicable.
e€1=US $1.03.
fExcluding radiotherapy costs.